Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 61

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 61
---
 of our Common Stock during the sales period, it is not possible at this stage to predict the number of shares that will
ultimately be issued.

You will experience immediate and substantial dilution in the book value per share of the Common Stock you purchase in the offering.

The shares of Common Stock in this offering, if any, will be sold from time to time at various prices. The offering
price per share of Common Stock in this offering may exceed the net tangible book value per share of our Common Stock outstanding prior to this offering. After giving effect to the sale of shares of our Common Stock in the aggregate amount of
$50,000,000 in this offering at an assumed public offering price of $2.48 per share (which was the last reported sale price of shares of our Common Stock on the Nasdaq Capital Market on October 30, 2025), and after deducting estimated offering
expenses and after deducting estimated sales agent commissions payable by us, our as adjusted net tangible book value as of June 30, 2025 would have been approximately $45,984,364 or approximately $0.66 per share of Common Stock. This
represents an immediate increase in net tangible book value of approximately $0.70 per share to existing stockholders and an immediate dilution of approximately $1.82 per share to new investors. See the section entitled “Dilution” below
for a more detailed illustration of the dilution you would incur if you participate in this offering.

S-7

USE OF PROCEEDS

We may issue and sell shares of our Common Stock having an aggregate offering price of up to $50,000,000 from time to time using this
prospectus supplement, before deducting sales agent commissions and expenses. The amount of proceeds we will receive from this offering, if any, will depend upon the number of shares of Common Stock sold and the market price at which they are sold.
Because there is no minimum offering amount required as a condition to this offering, the actual total offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will be able to sell
any shares under or fully utilize the Sales Agreement with the Sales Agent.

We currently intend to use the net proceeds from the sale of
the securities offered under this prospectus supplement for working capital and general corporate purposes.

Although we have identified
some potential uses of the net proceeds to be received from this offering, we cannot specify